- Home
- BLW vs XOMA Comparison
BLW vs XOMA Comparison
Compare BLW & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLW
- XOMA
- Stock Information
- Founded
- BLW 2003
- XOMA 1981
- Country
- BLW United States
- XOMA United States
- Employees
- BLW N/A
- XOMA N/A
- Industry
- BLW Other Consumer Services
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- BLW Consumer Discretionary
- XOMA Health Care
- Exchange
- BLW Nasdaq
- XOMA Nasdaq
- Market Cap
- BLW 533.4M
- XOMA 457.6M
- IPO Year
- BLW N/A
- XOMA N/A
- Fundamental
- Price
- BLW $13.91
- XOMA $33.53
- Analyst Decision
- BLW
- XOMA Strong Buy
- Analyst Count
- BLW 0
- XOMA 2
- Target Price
- BLW N/A
- XOMA $69.50
- AVG Volume (30 Days)
- BLW 85.9K
- XOMA 42.6K
- Earning Date
- BLW 01-01-0001
- XOMA 11-05-2025
- Dividend Yield
- BLW 8.83%
- XOMA N/A
- EPS Growth
- BLW N/A
- XOMA N/A
- EPS
- BLW 1.81
- XOMA N/A
- Revenue
- BLW N/A
- XOMA $44,952,000.00
- Revenue This Year
- BLW N/A
- XOMA $88.91
- Revenue Next Year
- BLW N/A
- XOMA $13.80
- P/E Ratio
- BLW $7.73
- XOMA N/A
- Revenue Growth
- BLW N/A
- XOMA 194.98
- 52 Week Low
- BLW $12.35
- XOMA $18.35
- 52 Week High
- BLW $14.26
- XOMA $39.92
- Technical
- Relative Strength Index (RSI)
- BLW 47.41
- XOMA 44.52
- Support Level
- BLW $13.81
- XOMA $31.97
- Resistance Level
- BLW $13.97
- XOMA $33.90
- Average True Range (ATR)
- BLW 0.08
- XOMA 1.36
- MACD
- BLW 0.02
- XOMA -0.19
- Stochastic Oscillator
- BLW 69.57
- XOMA 45.53
About BLW Blackrock Limited Duration Income Trust
Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.